RESEARCH

Open Access

The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran

Aziz Rezapour^{1,2†}, Andrew J. Palmer^{3,4†}, Vahid Alipour^{1,2}, Marjan Hajahmadi⁵ and Abdosaleh Jafari^{6*}

Abstract

Background: B-type natriuretic peptide (BNP) is commonly used as a diagnostic method for patients with heart failure. This study was designed to evaluate the cost-effectiveness of BNP compared to standard clinical assessment in outpatients with heart failure with reduced ejection fraction (HFrEF) in Tehran, Iran.

Methods: This study was a cost-effectiveness analysis carried on 400 HFrEF outpatients > 45 years who were admitted to Rasoul Akram General Hospital of Tehran, Iran. A Markov model with a lifetime horizon was developed to evaluate economic and clinical outcomes for BNP and standard clinical assessment. Quality-adjusted life-years (QALYs), direct, and indirect costs collected from the patients.

Results: The results of this study indicated that mean QALYs and cost were estimated to be 2.18 QALYs and \$1835 for BNP and 2.07 and \$2376 for standard clinical assessment, respectively. In terms of reducing costs and increasing QALYs, BNP was dominant compared to standard clinical assessment. Also, BNP had an 85% probability of being cost-effective versus standard clinical assessment if the willingness to pay threshold is higher than \$20,800/QALY gained.

Conclusion: Based on the results of the present study, measuring BNP levels represents good value for money, decreasing costs and increasing QALYs compared to standard clinical assessment. It is suggested that the costs of the BNP test be covered by insurance in Iran. The result of the current study has important implications for policymakers in developing clinical guidelines for the diagnosis of heart failure.

Keywords: Cost-effectiveness, Heart failure, B-type natriuretic peptide, Markov model

Background

Heart failure (HF) is a significant cause of mortality, morbidity, and rehospitalization in developing countries. Despite the improvement and promotion of modern

diagnostic and therapeutic strategies, HF remains an important health problem. In heart failure, the heart cannot pump enough blood to sustain blood flow to meet the body's requirements for blood and oxygen [1–5]. The main causes of heart failure include coronary artery disease, high blood pressure, atrial fibrillation, valvular heart disease, excess alcohol use, and infection. Based on the ability of the left ventricle to contract, or to relax, there are two types of left ventricular heart failure: heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) [6].

*Correspondence: abdosaleh.jafari@gmail.com

[†]Aziz Rezapour and Andrew J. Palmer had equal participation as the first author and we would like to consider both as co-first authors

⁶ Health Human Resources Research Centre, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Full list of author information is available at the end of the article

© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

The national burden of disease study in Iran showed the burden of cardiovascular disease will increase sharply in Iran post-2021, primarily due to the aging population [7]. Furthermore, in Iran, 79% of deaths related to chronic diseases are attributed to cardiovascular disease [8–11]. B-type Natriuretic Peptide (BNP) is a cardiac neuro-hormone released from the left ventricles in response to abnormal loading condition and is predictive of left-ventricular function and of prognosis [12–16]. Treatment intervention for patients with HF is usually based on clinical assessment [17]. Based on the guideline for the management of chronic heart failure in Iran, heart failure is confirmed by obtaining an accurate and complete medical history, clinical examination, and diagnostic tests. For all patients with heart failure with an ejection fraction less than 40%, Renin-angiotensin system inhibitor, in addition to beta-blocker, is recommended to reduce hospitalization due to heart failure or premature death. An electrocardiogram (ECG) is also advised to detect heart rhythm, heart rate, and other related disorders [18].

Recent meta-analyses have demonstrated that BNP-guided therapy did not decrease mortality but decreased HF hospitalization [19]. Guidelines from the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) recommend the use of BNP or NT-proBNP as a class I indication in the diagnosis of heart failure in ambulatory patients with dyspnea [20] however, limited number of studies have been performed on the cost-effectiveness of BNP [21].

Cost-effectiveness analysis is a comparative analysis of two or more interventions based on their costs and effectiveness. Given the limited resources in the health system of developing countries, selecting and implementing cost-effective interventions can improve allocative efficiency [22, 23]. Our previous study, using a systematic review, indicated that use of BNP in patients with heart failure may reduce costs and increase quality-adjusted life years (QALYs) [24]. However, these previous studies designed and conducted in high-income countries from the perspective of the health system and provider, thus it is of limited relevance to the Iranian context. We have therefore assessed the cost-effectiveness of BNP compared to standard clinical assessment in patients with heart failure in Iran from the societal perspective. The results of this study can assist policymakers to select cost-effective interventions for patients with heart failure.

Methods

Study design and study population

This study was a cost-effectiveness analysis conducted in patients who were admitted to Rasoul Akram General Hospital of Tehran, Iran for heart failure.

In this study, 400 HFrEF outpatients >45 years were followed up from August 2018 to August 2019. Patients were divided into two groups: standard clinical assessment group and BNP group. Standard clinical assessment of HF included medical history and physical examination. In the BNP arm, adjunctive testing included in addition to medical history and physical examination, with BNP measured each month from the time of admission. In this study we have excluded patients with factors influencing the BNP level including patients with high and low body mass index, glomerular filtration rate <50 mL/min/1.73m², cerebrovascular disease, pulmonary embolism and, atrial fibrillation or any acute inflammation.

A five-state Markov model was developed to examine the economic effect of the clinical outcomes using hypothetical cohort of 1000 HF patients over a lifetime horizon (Fig. 1). This model was formerly validated by Delea et al. to examine the cost-effectiveness of carvedilol [25]. Given the time horizon was more than one year, costs and QALYs were discounted with an annual rate of 5.8% [26] and 3%, respectively [27]. Health states within the model based on the number of previous HF hospitalizations. The number of rehospitalisations is a valid proxy for disease progression in patients with HF [28]. During each month, patients stay in the current health state without hospitalization or are readmitted and move to the next state. The following Markov assumption were used in this study: transitions between different health states occur in one-month cycles, the distribution of patients in the model begins from the state of no rehospitalization, deaths due to natural factors in each cycle of the model based on age-specific mortality rates may occur for any reason, each patient can stay in the same states or move to the next states.

Model parameters

We used four sets of parameters in the Markov model (Tables 1 and 2); the sources of these data are described as follows:

Quality of life

In the present study, QALYs were considered as the effectiveness measure and the utility of standard clinical assessment was measured with the EQ-5D-3L questionnaire. This questionnaire consisted of five dimensions such as mobility, self-care, pain/discomfort, and anxiety/depression [23]. The weights of this questionnaire have been previously estimated for Iran [29]. First, using the weighted scores, the utility (between zero and one) was estimated and then the QALYs were calculated by multiplying the amount of utility in the duration of time spent in the health state. 200 patients were interviewed in each treatment group and answered the EQ-5D questionnaire.

Fig. 1 Schematic diagram of Markov model. In this diagram, ovals represent health states; arrows represent all possible transitions between health states. During each month, patients stay in the current health state without hospitalization or are readmitted and move to the next state

The data was collected in this part of the study by interviewing the patient. At the beginning of each interview, the overall goal of the interview was explained to each patient separately. Patients who were interested in participating in the study answered the questions voluntarily.

Cost

Resource use was taken from the patient-level data and a bottom-up approach was applied to estimate the cost. The cost year was 2019 and the costs were identified and measured from the societal perspective. These items included medical and non-medical direct costs and indirect costs (lost productivity). 200 patients were interviewed in each treatment group and completed a data collection form. The data collection form was used to collect data, consisting of two parts: the first part collected demographic data of the patients and the second section collected information about the costs of physician visits, heart medications, BNP test, diagnostic and laboratory services, hospitalization and rehospitalization, nursing, special equipment, private service, accommodation

and traveling. The costs of productivity loss due to heart failure were estimated by employing the human capital approach [30].

Transitional probabilities

The transitional probabilities of different health states and probabilities of HF-related deaths were taken from Gohler's study [28]. To include other-cause mortality, we used the probabilities from age-specific Iranian life tables (Table 2) [31].

Relative risk

We used a relative risk in the model to adjust a baseline risk. The Relative risk of serial BNP for BNP vs standard clinical assessment (Table 1) was derived from the meta-analysis that was recently performed by Pufuleteiu et al. 2018. In the Pufuleteiu's study, the effectiveness of 14 eligible randomized controlled trials related to serial BNP were examined [19].

Table 1 Input parameters used in economic model

Variable	Mean	SD	Distribution	Source
Prob NRH to NRH	0.168	0.37	Beta	Göhler et al. [30]
Prob NRH to D	0.067	0.24	Beta	Göhler et al. [30]
Prob RH1 to RH1	0.213	0.36	Beta	Göhler et al. [30]
Prob RH1 to D	0.075	0.025	Beta	Göhler et al. [30]
Prob RH2 to RH2	0.268	0.37	Beta	Göhler et al. [30]
Prob RH2 to D	0.085	0.32	Beta	Göhler et al. [30]
Prob RH3 to D	0.095	0.33	Beta	Göhler et al. [30]
RR	0.81	5	LN	Pufulete et al. [16]
CostNRH_B	\$309	67	Gamma	Calculated
Cost RH1_B	\$446	100	Gamma	Calculated
Cost RH2_B	\$585	175	Gamma	Calculated
Cost RH3_B	\$861	249	Gamma	Calculated
Cost NRH_CA	\$272	65	Gamma	Calculated
Cost RH1_CA	\$548	153	Gamma	Calculated
Cost RH2_CA	\$824	247	Gamma	Calculated
Cost RH3_CA	\$1100	341	Gamma	Calculated
Utility NRH	0.85	0.23	Beta	Calculated
Utility RH1	0.828	0.25	Beta	Calculated
Utility RH2	0.809	0.26	Beta	Calculated
Utility RH3	0.777	0.24	Beta	Calculated

SD, standard deviation; Prob, probability; NRH, no rehospitalization; RH1, rehospitalization 1; RH2, rehospitalization 2; RH3, rehospitalization3; B, B-type natriuretic peptide (BNP); CA, clinical assessment; RR, relative risk; LN, Log-Normal

Cost-effectiveness analysis

Expected costs, QALYs and incremental cost-effectiveness ratio (ICER) were calculated. ICER was defined as the ratio of the difference between the costs of two alternatives to the difference between their effectiveness [22]. In addition, 95% confidence intervals (CIs) were calculated for costs and QALYs using the non-parametric bootstrapping approach [32].

Sensitivity analysis

Deterministic sensitivity analysis (tornado diagram) and probabilistic sensitivity analysis (PSA) was performed. In the probabilistic sensitivity analysis, probability distributions for the parameters were selected and Monte Carlo simulation was performed using 1000 samples. PSA results were indicated using the cost-effectiveness acceptability curves and incremental cost-effectiveness scatter plot [33]. We also performed two scenario analyses. We first used

EQ-5D values from Emrani's study [34]. Our second scenario included different time horizon (10 and 20 years).

Results

The results showed that the mean cost of BNP and standard clinical assessment were \$682 and \$649, respectively, in which the highest and lowest mean costs per patient were the direct medical costs and direct non-medical costs. The major costs in BNP and standard clinical assessments were related to the costs of medications used (\$255 and \$196, respectively) and diagnostic tests (\$189 and \$141, respectively) (Additional file 1). The result also indicated compared with standard clinical assessment; BNP patients had more significant improvements in the dimensions of mobility, self-care, and usual activities. (Additional file 2).

The expected QALYs and costs for patients who receive BNP and standard clinical assessment are shown in Table 3. According to this table, mean QALYs and cost were estimated to be 2.18 and \$1835 for BNP and 2.07 and \$2376 for standard clinical assessment, respectively. Although the incremental QALYs (0.11) and cost saving (\$541) are relatively small, it seems that BNP is cost-effective compared to standard clinical assessment.

Cost-effectiveness results in different age groups are shown in Table 4. BNP was dominant in the 45–55 years age group and cost-effective in 55–65 and 65–75 years age groups. Given that any economic evaluation study is associated with uncertainty, in this study, the robustness of the result was examined using one-way and probabilistic sensitivity analysis. In one-way sensitivity analysis, the value of each variable was increased and decreased by 20% separately and a tornado diagram was generated to identify the individual parameters with the greatest impact on the outcome. Based on the tornado diagram in Fig. 2, changes in most of the input

Table 3 The result of cost-effectiveness analysis

Strategy	Cost (USD)	QALYs	ΔC	ΔQALYs	BNP vs. Standard clinical assessment
BNP	1835	2.18	– 541	0.11	Dominant
Standard clinical assessment	2376	2.07			

QALYs, quality-adjusted life years; ΔC, cost difference; ΔQALYs, QALY difference

Table 2 All cause mortality rate by age in Iran

Age (range)	45–49	50–54	55–59	60–64	65–69	70–74	75–79	80–84	85 +
Mortality rate (%)	0.2	0.4	0.55	0.95	1.85	3.55	7.4	11.65	21.8

Table 4 Cost-effectiveness results in three patient subgroups

Subgroup	BNP		Standard clinical assessment		Incremental cost per QALY gained (BNP vs. standard clinical Assessment)
	Cost (USD)	QALYs	Cost (USD)	QALYs	
45–55 years	\$1100	2.07	\$1280	1.24	Dominant
55–65 years	\$1540	1.65	\$1400	1.35	USD 466
65–75 years	\$2700	1.24	\$2050	1.02	USD 2954

BNP, B-type natriuretic peptide; QALYs, quality-adjusted life-years; USD, United States Dollars

parameters had few effects on the incremental cost-effectiveness ratio. Moreover, The ICER had the highest sensitivities to the increase in the cost of rehospitalization3 in the BNP arm. Figure 3 shows the results of the probabilistic sensitivity analysis using Monte Carlo simulation of incremental costs and QALYs of BNP vs. standard clinical assessment. For each of the 1000 simulations, values for parameters were randomly selected from their probability distributions. The results showed that BNP was more cost-effective than standard clinical assessment with a maximum willingness to pay

threshold of USD20800 calculated based on WHO method (three times of per capita GDP, USD20800) [35]. In Fig. 4, cost-effectiveness acceptability curve (CEAC) showed that BNP compared with standard clinical assessment, was more cost-effective in the majority of willingness to pay so that BNP has an 85% probability of being more cost-effective in the thresholds higher than USD20800. Table 5, indicated the results of the scenario analysis. Based on this table, the most influential parameter was the use of EQ-5D values

Fig. 3 The results of the probabilistic sensitivity analysis. Each point indicates the differences in the costs and effectiveness of BNP vs. standard clinical assessment. The results showed that BNP was more cost-effective than standard clinical assessment with a maximum willingness to pay threshold of USD20800

from Emrani's study. Nonetheless, the BNP remained cost-effective in all scenario analyses.

Discussion

To our knowledge, this study was the first cost-effectiveness analysis related to diagnostic interventions in patients with heart failure in Iran. In the present study, we directly estimated cost and QALYs using patient-level data instead of using data from the published literature. In most studies, the utility value was taken from a literature review, which could lead to misestimating of QALYs.

Based on the results, it seems that the use of BNP may reduce cost compared to the standard clinical assessment and improve QALYs. Faster diagnosis of heart failure with BNP can prevent from signs and symptoms (such as, shortness of breath with activity, fatigue and weakness, rapid or irregular heartbeat, swelling of the belly area (abdomen), difficulty concentrating or decreased alertness) and increase patients utility. Other studies confirm the results of the present study. For example, Moertl et al. indicated that the measurement

of BNP level compared with the usual care and multi-disciplinary care reduced costs and increased QALY [36]. Laramée et al. found that the serial BNP measurement by a specialist was the most cost-effective option compared to clinical assessment and usual care, but it is not cost-effective in people aged over 75 years of age [17]. In a similar study, Mohiuddin et al. indicated that BNP-guided care in younger patients with heart failure and reduced ejection fraction was more cost-effective than the clinical care [21]. In a similar study, Morimoto et al. showed that BNP was a cost-effective alternative to the clinical care and increased QALY and decreased costs [37]. Siebert et al. showed that the use of BNP reduced the use of echocardiography and initial hospitalization by 58% and 13%, respectively [38]. Pufulete et al. indicated that the efficacy of BNP-guided therapy in specialist HF clinics is uncertain and in the cost-effectiveness model, in patients aged <75 years with HFrEF or HFpEF, BNP-guided therapy improves median survival with a small QALY gain but higher lifetime costs [39].

Fig. 4 Cost-effectiveness acceptability curve. The curve shows that BNP compared with standard clinical assessment was more cost-effective at the majority of willingness to pay thresholds. BNP has an 85% chance of being cost-effective versus standard clinical assessment with thresholds higher than USD20800

Table 5 Scenario analysis

Strategy	Cost (USD)	QALYs	ΔC	ΔQALYs	BNP vs. Standard clinical assessment
Scenario 1: EQ-5D values from Emrani study					
BNP	1835	1.9	− 541	0.12	Dominant
Standard clinical assessment	2376	1.78			
Scenario 2: time horizon 10 years					
BNP	1805	2.15	− 551	0.15	Dominant
Standard clinical assessment	2356	2			
Scenario 2: time horizon 20 years					
BNP	1832	2.18	542	0.11	Dominant
Standard clinical assessment	2374	2.07			

In addition, the sensitivity analyses show that there is a large amount of uncertainty associated with these results and that the results are highly sensitive to a number of key inputs (the cost values in particular). Given that both BNP and clinical assessment can be performed in hospitals of Iran, the results of this study can be generalized to other Iranian hospitals. As to

other countries, other factors such as the degree of costs covered by insurance organizations, the patients' willingness to pay, the incidence and prevalence of disease, difference in clinical guidelines, relative prices, reimbursement system and threshold should be considered. The few numbers of studies have been performed on the cost-effectiveness of diagnostic methods

in patients with heart failure in developing countries, while the majority of people with heart diseases are living in countries with middle and low income and it needs to be performed more economic evaluation researches in this field in developing countries. This study had some limitations. First, the efficacy of diagnostic methods in patients with heart failure is mainly dependent on factors such as the sensitivity and specificity of laboratory tests and the period of patient follow-up. Second, we used a hypothetical cohort model; the real condition may be different from our model. However, the strength of our study was to use societal perspective, measure the direct and indirect cost of the patient, and use validated weight of utility for the Iranian population.

According to results of the current study, measuring BNP levels probably represents good value for money. It reduced costs and increased QALYs compared to standard clinical assessment. Given the result of this study, it is suggested that the cost of the BNP test be covered by insurance because of its high costs for heart failure patients. Moreover, it suggested that when developing clinical guidelines for the diagnosis of heart failure, policymakers should approve monitoring BNP levels in heart failure patients in Iran.

Abbreviations

BNP: B-type natriuretic peptide; HFrEF: Heart failure with reduced ejection fraction; QALYs: Quality-adjusted life years; PSA: Probabilistic sensitivity analysis; CEAC: Cost-effectiveness acceptability curve; ICER: Incremental cost-effectiveness ratio; ACCF: American College of Cardiology Foundation; HFpEF: Heart failure with preserved ejection fraction; AHA: American Heart Association; NT-proBNP: N-terminal pro-B-type natriuretic peptide.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12962-021-00334-z>.

Additional file 1. Direct and Indirect Costs in BNP and standard clinical assessment.

Additional file 2. Mean of disutility in study groups.

Acknowledgements

The researchers would like to acknowledge all patients who participated in the study.

Authors' contributions

AR, VA, MH and AJ contributed to conceiving and designing the study. The data was collected by AJ and was analyzed and interpreted jointly by AJP, AR, VA and AJ. All authors wrote the final manuscript. All authors read and approved the final manuscript.

Funding

This article was extracted from a research project supported financially by Health Management and Economics Research Center, Iran University of Medical Sciences, grant's No. 12580.

Availability of data and materials

All related data were displayed in the manuscript. Further information regarding the data can be obtained by contacting the corresponding authors.

Declarations

Ethics approval and consent to participate

This study approved by Ethics Committee of Iran University of Medical Sciences and received Ethical code: IR.IUMS.REC.1397.834.

Consent for publication

Not applicable.

Competing interests

The authors declare that there is no conflict of interest.

Author details

¹Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. ²Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. ³Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia. ⁴Centre for Health Policy, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia. ⁵Cardiologist, Fellowship in Heart Failure and Cardiac Transplantation, Cardiovascular Department, Rasoul Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran. ⁶Health Human Resources Research Centre, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: 16 August 2021 Accepted: 4 December 2021

Published online: 23 December 2021

References

1. MedicineNet. Definition of heart failure. https://www.medicinenet.com/heart_failure/definition.htm.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. *Circulation*. 2011;123:933–44.
3. Liu LC, Damman K, Lipsic E, Maass AH, Rienstra M, Westenbrink BD. Heart failure highlights in 2012–2013. *Eur J Heart Fail*. 2014;16:122–32.
4. Stewart S, MacIntyre K, Capewell S, McMurray J. Heart failure and the aging population: an increasing burden in the 21st century? *Heart*. 2003;89:49–53.
5. Rathi S, Deedwania PC. The epidemiology and pathophysiology of heart failure. *Med Clin*. 2012;96:881–90.
6. Conditions NCCfC. Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care. London: Royal College of Physicians; 2003.
7. Sadeghi M, Haghdoust AA, Bahrampour A, Dehghani M. Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: the impact of demographic changes. *Iran J Public Health*. 2017;46:506.
8. Forouzanfar MH, Sepanlou SG, Shahrzaz S, Naghavi P, Pourmalek F, Lozano R, et al. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. *Arch Iran Med*. 2014;17:304.
9. Hatmi Z, Tahvildari S, Motlag AG, Kashani AS. Prevalence of coronary artery disease risk factors in Iran: a population based survey. *BMC Cardiovasc Disord*. 2007;7:32.
10. Fakhrazadeh H, Bandarian F, Adibi H, Samavat T, Malekafzali H, Hodjatza-deh E, et al. Coronary heart disease and associated risk factors in Qazvin: a population-based study. *EMHJ*. 2008;14:33–41.
11. Naghavi M. Features of death in 18 province of Iran in 2000. Tehran: Tandis Publications; 2002.
12. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. *Am Heart J*. 2009;158:422–30.

13. Porapakham P, Porapakham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. *Arch Intern Med*. 2010;170:507–14.
14. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. *Heart*. 2009;95:1508–13.
15. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. *JAMA*. 2009;301:383–92.
16. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. *J Am Coll Cardiol*. 2009;55:53–60.
17. Laramée P, Wonderling D, Swain S, Al-Mohammad A, Mant J. Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. *Heart*. 2013;99:267–71.
18. Education TMOHaM. Guideline for the management of chronic heart failure in Iran. 2015.
19. Pufulete M, Maishman R, Dabner L, Higgins JP, Rogers CA, Dayer M, et al. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. *Syst Rev*. 2018;7:112.
20. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. *Practice Guidelines*. 2013;2013(62):e147–239.
21. Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. *BMJ Open*. 2016;6:e014010.
22. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. *Methods for the economic evaluation of health care programmes*. Oxford: Oxford University Press; 2005.
23. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. *Applied methods of cost-effectiveness analysis in healthcare*. Oxford: Oxford University Press; 2011.
24. Jafari A, Rezapour A, Hajahmadi M. Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. *Heart Fail Rev*. 2018;23:693–700.
25. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. *Am J Cardiol*. 1999;83:890–6.
26. Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. *J Econ Struct*. 2018;7:29.
27. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian M-A, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: decision analysis based on long-term clinical data and switchable treatments. *DARU J Pharm Sci*. 2013;21:50.
28. Göhler A, Conrads-Frank A, Worrell SS, Geisler BP, Halpern EF, Dietz R, et al. Decision-analytic evaluation of the clinical effectiveness and cost-effectiveness of management programmes in chronic heart failure. *Eur J Heart Fail*. 2008;10:1026–32.
29. Goudarzi R, Zeraati H, Sari AA, Rashidian A, Mohammad K. Population-based preference weights for the EQ-5D health states using the visual analogue scale (VAS) in Iran. *Iran Red Crescent Med J*. 2016;18:1–9.
30. Trovato MRJS. Human capital approach in the economic assessment of interventions for the reduction of seismic vulnerability in historic centres. *Sustainability*. 2020;12:8059.
31. Life tables by country Iran (Islamic Republic of). <https://apps.who.int/gho/data/?theme=main&vid=60760>.
32. Nixon RM, Wonderling D, Grieve RD. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared. *Health Econ*. 2010;19:316–33.
33. Limwattananon S. Handling uncertainty of the economic evaluation result: sensitivity analysis. *J Med Assoc Thai*. 2011;91:59.
34. Emrani Z, Akbariari A, Zeraati H, Olyaeemanesh A, Daroudi RJH. Health-related quality of life measured using the EQ-5D-5 L: population norms for the capital of Iran. *Health Qual Life Outcomes*. 2020;18:1–8.
35. Hutubessy R, Chisholm D, Edejer TT-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. *Cost Eff Resour Alloc*. 2003;1:8.
36. Moertl D, Steiner S, Coyle D, Berger R. Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. *Int J Technol Assess Health Care*. 2013;29:3–11.
37. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T. Is B-type natriuretic peptide-guided heart failure management cost-effective? *Int J Cardiol*. 2004;96:177–81.
38. Siebert U, Januzzi JL Jr, Beinfeld MT, Cameron R, Gazelle GS. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. *Am J Cardiol*. 2006;98:800–5.
39. Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers CA, et al. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. *Health Technol Assess*. 2017;21:1–150.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Rezapour, A;Palmer, AJ;Alipour, V;Hajahmadi, M;Jafari, A

Title:

The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran

Date:

2021-12-23

Citation:

Rezapour, A., Palmer, A. J., Alipour, V., Hajahmadi, M. & Jafari, A. (2021). The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran. COST EFFECTIVENESS AND RESOURCE ALLOCATION, 19 (1), <https://doi.org/10.1186/s12962-021-00334-z>.

Persistent Link:

<http://hdl.handle.net/11343/296058>

License:

[CC BY](#)